Pei Yu

Dr. Pei Yu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Toxicology Research
Verified
Journal Article
Closed access
PDF file
CZChu Zhang
Chu Zhang
YLYupei Liao
Yupei Liao
TLTangjia Li
Tangjia Li
HZHai-Jing Zhong
Hai-Jing Zhong
LSLuchen Shan
Luchen Shan
LXLipeng Xu
Lipeng Xu
The 2022 US Cancer Statistics show that breast cancer is one of the most common cancers in women. Epidemiology has shown that adding flavonoids to the diet inhibits cancers that arise in particular women, such as cervical cancer, ovarian cancer, and breast cancer. Although there have been research reports on apigenin (API) and breast cancer, its anti-tumor effect and potential mechanism on breast cancer have not yet been clarified. Therefore, in this study, we used 4T1 cells and a 4T1 xenograft tumor mouse model to investigate the antitumor effect of API on breast cancer and its underlying mechanism. In vitro, we used MTT, transwell, staining, and western blotting to investigate the inhibitory effect of apigenin on 4T1 and the underlying molecular mechanism. In vivo by establishing a xenograft tumor model, using immunohistochemistry, and flow cytometry to study the inhibitory effect of apigenin on solid breast tumors and its effect on the tumor immune microenvironment. The results showed that API can induce breast cancer cell apoptosis through the PI3K/AKT/Nrf2 pathway and can improve the tumor immune microenvironment in mice with breast tumors, thereby inhibiting the growth of breast cancer. Thus, API may be a promising agent for breast cancer treatment.

2 April 2024 in Journal of Chromatography A
Verified
Journal Article
Closed access
LLLiang Lai
Liang Lai
MZMengyao Zhang
Mengyao Zhang
TLTong Li
Tong Li
JQJiahuan Qu
Jiahuan Qu
DXDongsheng Xu
Dongsheng Xu
zhengjin jiangzhengjin jiang
zhengjin jiang

25 August 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YLYangwen Luo
Yangwen Luo
LSLuchen Shan
Luchen Shan
LXLipeng Xu
Lipeng Xu
SPSrinivas Patnala
Srinivas Patnala
IKIsadore Kanfer
Isadore Kanfer
JXJun Xu
Jun Xu
Sceletium tortuosum (SCT) has been utilized medicinally by indigenous Koi-San people purportedly for mood elevation. SCT extracts are reported to be neuroprotective and have efficacy in improving cognition. However, it is still unclear which of the pharmacological mechanisms of SCT contribute to the therapeutic potential for neurodegenerative disorders. Hence, this study investigated two aspects–firstly, the abilities of neuroprotective sub-fractions from SCT on scavenging radicals, inhibiting some usual targets relevant to Alzheimer’s disease (AD) or Parkinson’s disease (PD), and secondly utilizing the network pharmacology related methods to search probable mechanisms using Surflex-Dock program to show the key targets and corresponding SCT constituents. The results indicated sub-fractions from SCT could scavenge 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical, inhibit acetylcholinesterase (AChE), monoamine oxidase type B (MAO-B) and N-methyl-D-aspartic acid receptor (NMDAR). Furthermore, the results of gene ontology and docking analyses indicated the key targets involved in the probable treatment of AD or PD might be AChE, MAO-B, NMDAR subunit2B (GluN2B-NMDAR), adenosine A2A receptor and cannabinoid receptor 2, and the corresponding constituents in Sceletium tortuosum might be N-trans-feruloyl-3-methyldopamine, dihydrojoubertiamine and other mesembrine type alkaloids. In summary, this study has provided new evidence for the therapeutic potential of SCT in the treatment of AD or PD, as well as the key targets and notable constituents in SCT. Therefore, we propose SCT could be a natural chemical resource for lead compounds in the treatment of neurodegenerative disorders.

16 October 2024 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
LTLiu Tao
Liu Tao
CYChuanjie Yao
Chuanjie Yao
SWSijie Wang
Sijie Wang
YYYuying Ye
Yuying Ye
ZTZhengchao Tu
Zhengchao Tu
PYPei Yu
Pei Yu

1 January 2024 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
CQChaoming Qiu
Chaoming Qiu
XYXifei Yang
Xifei Yang
PYPei Yu
Pei Yu
Sarcopenia is becoming prevalent in older or inactive patients, which is placing a heavy burden on the social health system. Studies on the pathogenesis of sarcopenia mainly focus on adipose tissue, myoglobin autophagy, and mitochondrial dysfunction. Up to now, non-drug treatment has been the main way to treat sarcopenia, and there are no drugs specially approved for the treatment of sarcopenia. Here, the pathophysiology and treatment methods of sarcopenia have been summarized, and new drugs for sarcopenia to be researched and developed in the future have been prospected.

8 June 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ZLZixin Li
Zixin Li
LSLuchen Shan
Luchen Shan
PYPei Yu
Pei Yu